S-1 · primary and resale
Issued 2023
Proposed maximum
Shares registered
- Filed
- Effective
ENGN$1.47+1.38%
enGene Therapeutics Inc.
Sector: Biological Products, (No Diagnostic Substances)Industry: BiotechnologyCountry: CAExchange: Nasdaq
Mkt Cap:$98.51M
Float & O/S:
Inst Own:
DilutionScan read 32 of enGene Therapeutics Inc.'s SEC filings and found 5 warrant series, 2 convertibles, 2 ATM programs, 3 shelf registrations, 1 S-1 registration and 1 completed offering on file for ENGN. The latest dilution event on file is ATM sales on Jul 31, 2026. Analysis updated Oct 6, 2026.
Signal8 Summary
19d old
ENGN
Pre-revenue biotech funded through BLA filing
- Business
- MixedNo revenue, $117M net loss, but $266.3M cash, 28-month runway
- Stock risk
- High$104.5M micro-cap, shares +14.5% YoY, 113% overhang supply
Snapshot
enGene is a clinical-stage biotech with no revenue, posting a $117.3M net loss in FY 2025 and burning roughly $100.7M in free cash flow. It holds $266.3M in cash against modest $33.3M debt, and Signal8 models about 28 months of runway.
What's Happening Right Now
- : enGene will host an October 15, 2026 webinar detailing preclinical data behind pairing a surfactant bladder rinse with detalimogene in its NMIBC program.
- : The Q3 10-Q showed a $32.5M quarterly net loss and $464.5M accumulated deficit; the company cut its workforce ~50% in June 2026 to preserve cash and still plans a BLA submission in Q4 2026.
- : enGene reported Q3 FY2026 results, with focus shifting to maturing LEGEND pivotal-cohort data and an upcoming FDA engagement on a BLA filing for detalimogene.
- : An updated corporate presentation on July 24, 2026 showed the pivotal cohort's 54% complete response rate and 43% six-month response rate, with a planned BLA submission in H2 2026.
- : Chairman Richard Glickman resigned effective July 15, 2026 after 14+ years; director Michael Heffernan was appointed as the new Chairman.
- : Registered $400.00M of securities for sale on Form S-3.
- : Issued warrants over 41K shares.
- : Raised $149.50M in gross proceeds through a public offering, with warrants over 2.74M shares.
Raise routes on file: active ATM + effective shelf · latest dilution event 95 days ago
Overall Risk
Offering Ability
Overhead Supply
Historical
Cash Need
AI dilution summary
The dominant contractual driver and its mechanism, then each further driver ranked.
Latest dilution event
Jul 31, 2026 · ATM Sale
Every warrant, convertible, ATM and shelf, cited to the filing
A free account reads 3 tickers a day in full
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
Share count and cash history
Shares outstanding, potential dilution and cash over time
Superseded
Warrant
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Warrant
Issued 2023
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Warrant
Issued 2026
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Warrant
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Warrant
Issued 2025
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Convertible
Principal
Conversion Price
Remaining principal
- Shares on conversion
- Interest rate
- Maturity
Convertible
Principal
Conversion Price
Remaining principal
- Shares on conversion
- Interest rate
- Maturity
ATM program
Issued 2024
Total capacity
Sold to date
Remaining capacity
- Sales agent
- Agreement date
- Commission
ATM program
Issued 2026
Total capacity
Sold to date
Remaining capacity
- Sales agent
- Agreement date
- Commission
S-3 shelf registration
Issued 2026
Total capacity
Remaining
- Filed
- Effective
- Expires
- Baby shelf
S-3 shelf registration
Issued 2024
Total capacity
Remaining
- Filed
- Effective
- Expires
- Baby shelf
S-3 shelf registration
Issued 2024
Total capacity
Remaining
- Filed
- Effective
- Expires
- Baby shelf
Public offering
Issued 2025
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
Know who's about to sell into your ENGN trade
Exercise prices, conversion terms, shelf headroom and the filing sentence behind every number.
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
